MediciNova Competitors

MediciNova (NASDAQ:MNOV) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk.

Profitability

This table compares MediciNova and Annexon's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for MediciNova and Annexon, as reported by MarketBeat.

MediciNova currently has a consensus price target of $13.00, suggesting a potential upside of 180.78%. Annexon has a consensus price target of $34.3333, suggesting a potential upside of 44.02%. Given MediciNova's higher possible upside, equities research analysts clearly believe MediciNova is more favorable than Annexon.

Earnings and Valuation

This table compares MediciNova and Annexon's top-line revenue, earnings per share and valuation.

Institutional & Insider Ownership

21.7% of MediciNova shares are owned by institutional investors. Comparatively, 91.2% of Annexon shares are owned by institutional investors. 16.0% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

MediciNova beats Annexon on 5 of the 7 factors compared between the two stocks.

Affimed (NASDAQ:AFMD) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.

Valuation & Earnings

This table compares Affimed and MediciNova's revenue, earnings per share and valuation.

MediciNova has lower revenue, but higher earnings than Affimed.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Affimed and MediciNova, as reported by MarketBeat.com.

Affimed currently has a consensus price target of $13.80, indicating a potential upside of 34.37%. MediciNova has a consensus price target of $13.00, indicating a potential upside of 180.78%. Given MediciNova's higher possible upside, analysts plainly believe MediciNova is more favorable than Affimed.

Profitability

This table compares Affimed and MediciNova's net margins, return on equity and return on assets.

Insider & Institutional Ownership

52.3% of Affimed shares are held by institutional investors. Comparatively, 21.7% of MediciNova shares are held by institutional investors. 16.0% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Affimed has a beta of 2.81, meaning that its share price is 181% more volatile than the S&P 500. Comparatively, MediciNova has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.

Summary

MediciNova beats Affimed on 6 of the 10 factors compared between the two stocks.

MediciNova (NASDAQ:MNOV) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.

Insider and Institutional Ownership

21.7% of MediciNova shares are owned by institutional investors. Comparatively, 59.4% of Dyne Therapeutics shares are owned by institutional investors. 16.0% of MediciNova shares are owned by insiders. Comparatively, 1.8% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares MediciNova and Dyne Therapeutics' gross revenue, earnings per share and valuation.

Profitability

This table compares MediciNova and Dyne Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for MediciNova and Dyne Therapeutics, as reported by MarketBeat.com.

MediciNova presently has a consensus target price of $13.00, suggesting a potential upside of 180.78%. Dyne Therapeutics has a consensus target price of $34.25, suggesting a potential upside of 95.38%. Given MediciNova's higher probable upside, research analysts plainly believe MediciNova is more favorable than Dyne Therapeutics.

Summary

Dyne Therapeutics beats MediciNova on 4 of the 6 factors compared between the two stocks.

MediciNova (NASDAQ:MNOV) and Merus (NASDAQ:MRUS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Valuation & Earnings

This table compares MediciNova and Merus' revenue, earnings per share (EPS) and valuation.

MediciNova has higher earnings, but lower revenue than Merus.

Insider and Institutional Ownership

21.7% of MediciNova shares are owned by institutional investors. Comparatively, 62.6% of Merus shares are owned by institutional investors. 16.0% of MediciNova shares are owned by company insiders. Comparatively, 7.4% of Merus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares MediciNova and Merus' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations for MediciNova and Merus, as reported by MarketBeat.

MediciNova presently has a consensus price target of $13.00, suggesting a potential upside of 180.78%. Merus has a consensus price target of $27.80, suggesting a potential upside of 17.80%. Given MediciNova's stronger consensus rating and higher probable upside, equities analysts plainly believe MediciNova is more favorable than Merus.

Volatility & Risk

MediciNova has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Merus has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Summary

MediciNova beats Merus on 8 of the 11 factors compared between the two stocks.

BioXcel Therapeutics (NASDAQ:BTAI) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership.

Analyst Ratings

This is a summary of recent ratings for BioXcel Therapeutics and MediciNova, as reported by MarketBeat.com.

BioXcel Therapeutics presently has a consensus price target of $101.8182, suggesting a potential upside of 183.30%. MediciNova has a consensus price target of $13.00, suggesting a potential upside of 180.78%. Given BioXcel Therapeutics' higher probable upside, equities research analysts clearly believe BioXcel Therapeutics is more favorable than MediciNova.

Profitability

This table compares BioXcel Therapeutics and MediciNova's net margins, return on equity and return on assets.

Insider & Institutional Ownership

48.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 21.7% of MediciNova shares are held by institutional investors. 9.4% of BioXcel Therapeutics shares are held by company insiders. Comparatively, 16.0% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

BioXcel Therapeutics has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, MediciNova has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.

Valuation and Earnings

This table compares BioXcel Therapeutics and MediciNova's revenue, earnings per share and valuation.

Summary

MediciNova beats BioXcel Therapeutics on 5 of the 8 factors compared between the two stocks.

MediciNova (NASDAQ:MNOV) and Epizyme (NASDAQ:EPZM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.

Insider and Institutional Ownership

21.7% of MediciNova shares are owned by institutional investors. Comparatively, 89.8% of Epizyme shares are owned by institutional investors. 16.0% of MediciNova shares are owned by company insiders. Comparatively, 16.3% of Epizyme shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares MediciNova and Epizyme's gross revenue, earnings per share and valuation.

MediciNova has higher earnings, but lower revenue than Epizyme.

Analyst Recommendations

This is a breakdown of current ratings and price targets for MediciNova and Epizyme, as reported by MarketBeat.com.

MediciNova currently has a consensus price target of $13.00, suggesting a potential upside of 180.78%. Epizyme has a consensus price target of $17.00, suggesting a potential upside of 102.62%. Given MediciNova's stronger consensus rating and higher probable upside, research analysts clearly believe MediciNova is more favorable than Epizyme.

Profitability

This table compares MediciNova and Epizyme's net margins, return on equity and return on assets.

Risk & Volatility

MediciNova has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Epizyme has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500.

Summary

MediciNova beats Epizyme on 6 of the 11 factors compared between the two stocks.